Total neoadjuvant therapy (TNT)

DRUG4 trials

Sponsors

Helsinki University Central Hospital, brenner baruch, Ankara Etlik City Hospital, St. James's Hospital, Ireland

Conditions

Colorectal CancerGLP-1Locally Advanced Rectal Cancer (LARC)Obesity &Amp; OverweightRectal Cancer PatientsTotal Neoadjuvant Therapy

Phase 2

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

RecruitingNCT06940388

brenner baruchLocally Advanced Rectal Cancer (LARC)

Start: 2025-07-23End: 2030-08-31Target: 134Updated: 2025-07-24

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

Not yet recruitingNCT07314528

St. James's Hospital, IrelandGLP-1, Locally Advanced Rectal Cancer (LARC), Obesity &Amp; Overweight +2

Start: 2026-04-30End: 2028-09-30Target: 42Updated: 2026-01-02

Unknown Phase

Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer

RecruitingNCT04842006

Helsinki University Central HospitalColorectal Cancer

Start: 2021-12-20End: 2031-12-31Target: 93Updated: 2023-03-06

AI-Based Prediction of Pathological Response in Rectal Cancer Patients Receiving Total Neoadjuvant Therapy

CompletedNCT07049627

Ankara Etlik City HospitalLocally Advanced Rectal Cancer (LARC)

Start: 2022-11-05End: 2024-12-31Updated: 2025-07-08

Related Papers

Predicting Pathologic Response in Locally Advanced Rectal Cancer Using Inflammatory, Nutritional, and Sarcopenia-Based Markers: A Regression and AI-Based Analysis (CINR-AI Study).

2025-10-16